Insulet Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Insulet Corporation on October 14, 2016. The filing details significant changes to the Company's Board of Directors and executive officer leadership structure.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Board Leadership: Patrick J. Sullivan, President and CEO, was appointed Chairman of the Board, effective immediately. He continues to serve as CEO.
- Lead Independent Director: Dr. Jessica Hopfield succeeded Dr. John Fallon as Lead Independent Director. Dr. Fallon remains an independent, outside director.
- Executive Officer Appointments: Shacey Petrovic was appointed President and Chief Operating Officer (COO), a newly created role. She will oversee the Drug Delivery product line.
- Executive Departure: Daniel Levangie, President of Drug Delivery, announced plans to retire at the end of 2016. Ms. Petrovic will assume his responsibilities.
Guidance, Outlook, and Risks
The filing references a press release issued on October 19, 2016, regarding these leadership changes. The document does not provide specific financial guidance, outlook, or discuss new material risks or contingencies beyond the operational transition of leadership.
Key Facts for Investor Verification
- Patrick J. Sullivan now holds the dual role of Chairman and CEO.
- Shacey Petrovic has been promoted to President and COO, taking over the Drug Delivery product line.
- Daniel Levangie is retiring at the end of 2016, with a transition period planned through year-end.
- Dr. Jessica Hopfield is the new Lead Independent Director.
- Seven of the eight Board seats are held by independent outside directors.